Screener
Castle Biosciences CSTL Net investment gains (losses)
Net investment gains (losses) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
| Interest income | 2,545 | 3,099 |
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
| Income tax expense (benefit) | 109 | (423) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's net investment gains (losses)?
- Castle Biosciences (CSTL) reported net investment gains (losses) of $2.02M in Q1 2026.
- How has Castle Biosciences's net investment gains (losses) changed year-over-year?
- Castle Biosciences's net investment gains (losses) increased by 241.9% year-over-year, from -$1.43M to $2.02M.
- What does net investment gains (losses) mean?
- Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.
Ask your AI about Castle Biosciences's net investment gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude